Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

Phase 4

Completed

Conditions: Clinically Isolated Syndrome
Multiple Sclerosis

Interventions: Drug: Ocrelizumab

First Posted Date: 2021-08-10

Last Posted Date: 2025-04-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 26

Registration Number: NCT04998851

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
University Of Colorado, Aurora, Colorado, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 5 locations

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

Phase 4

Active, not recruiting

Conditions: Clinically Isolated Syndrome
Multiple Sclerosis

Interventions: Drug: Ocrelizumab

First Posted Date: 2021-08-10

Last Posted Date: 2025-05-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 70

Registration Number: NCT04998812

Locations: 🇨🇭
Inselspital Bern, Bern, Switzerland
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇪🇸
Hosp. Clinico San Carlos, Madrid, Spain

and more 9 locations

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: Glofitamab
Drug: Tocilizumab
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Rituximab
Drug: Cyclophosphamide

First Posted Date: 2021-07-28

Last Posted Date: 2025-05-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 46

Registration Number: NCT04980222

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 20 locations

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Phase 3

Active, not recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo
Drug: Obinutuzumab
Drug: Acetaminophen/Paracetamol
Drug: Diphenhydramine hydrochloride
Drug: Methylprednisolone

First Posted Date: 2021-07-15

Last Posted Date: 2025-04-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 300

Registration Number: NCT04963296

Locations: 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸
Unity Health - White County Medical Center- Rheumatology, Searcy, Arkansas, United States
🇺🇸
Providence Medical Foundation, Fullerton, California, United States

and more 67 locations

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Phase 3

Terminated

Conditions: Generalized Myasthenia Gravis

Interventions: Other: Placebo
Drug: Satralizumab

First Posted Date: 2021-07-15

Last Posted Date: 2025-02-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 188

Registration Number: NCT04963270

Locations: 🇺🇸
Prairie Education and Research, O'Fallon, Illinois, United States
🇦🇷
Hospital Italiano, Caba, Argentina
🇦🇷
Hospital Ramos Mejía, Caba, Argentina

and more 73 locations

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Phase 3

Recruiting

Conditions: Early Breast Cancer

Interventions: Drug: Giredestrant
Drug: Endocrine Therapy of Physician's Choice
Drug: LHRH Agonist
Drug: Abemaciclib

First Posted Date: 2021-07-14

Last Posted Date: 2025-05-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 4200

Registration Number: NCT04961996

Locations: 🇦🇷
Hospital Alemán, Recoleta, Argentina
🇦🇷
Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina
🇧🇪
Centre Hospitalier Chrétien MontLégia, Liège, Belgium

and more 698 locations

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Phase 3

Active, not recruiting

Conditions: Atypical Hemolytic Uremic Syndrome

Interventions: Drug: Crovalimab

First Posted Date: 2021-07-12

Last Posted Date: 2025-06-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 41

Registration Number: NCT04958265

Locations: 🇺🇸
University of California Davis Medical Center, Sacramento, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Memorial Healthcare Systems, Hollywood, Florida, United States

and more 26 locations

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Phase 2

Terminated

Conditions: Gastric Cancer
Stomach Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2021-06-21

Last Posted Date: 2024-11-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 29

Registration Number: NCT04933227

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, China
🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳
Beijing Cancer Hospital, Beijing, China

and more 8 locations

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Giredestrant
Drug: Inavolisib
Drug: Trastuzumab Emtansine
Drug: Cobimetinib
Drug: Atezolizumab
Drug: Ipatasertib
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Abemaciclib
Drug: Palbociclib
Drug: Olaparib
Drug: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Drug: Letrozole
Drug: Cyclophosphamide

First Posted Date: 2021-06-18

Last Posted Date: 2025-03-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 176

Registration Number: NCT04931342

Locations: 🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Gustave Roussy, Villejuif CEDEX, France
🇺🇸
UCSF Helen Diller Family CCC, San Francisco, California, United States

and more 36 locations

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Inavolisib
Drug: Cetuximab
Drug: Bevacizumab
Drug: Atezolizumab
Drug: SY-5609
Drug: Divarasib
Drug: Tiragolumab
Drug: FOLFOX
Drug: FOLFIRI

First Posted Date: 2021-06-18

Last Posted Date: 2025-06-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 542

Registration Number: NCT04929223

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of
🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 70 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy